Decheng Capital LLC Q4 2025 Filing

Filed February 12, 2026

Portfolio Value

$743.4M

Holdings

19

Report Date

Q4 2025

Filing Type

13F-HR

All Holdings (19 positions)

#StockSharesValue% PortfolioType
1
CGONCG ONCOLOGY INC
6,371,669$264.6M35.59%
2
NUVBNuvation Bio Inc.
25,954,439$232.6M31.28%
3
UPBUpstream Bio Inc.
3,143,078$85.3M11.48%
4
AARDAARDVARK THERAPEUTICS INC
3,917,299$51.4M6.92%
5
LYELLyell Immunopharma, Inc.
692,050$21.3M2.87%
6
NAMSNEWAMSTERDAM PHARMA CO NV
592,057$20.8M2.79%
7
RVMDREVOLUTION MEDICINES INC(NSM)
200,000$15.9M2.14%
8
RCUSArcus Biosciences, Inc
541,559$12.9M1.74%
9
ACRSAclaris Therapeutics, Inc.
4,041,736$12.2M1.64%
10
EQEquillium Inc.
4,447,308$6.9M0.93%
11
BYSIBeyondSpring Inc.
3,800,702$6.2M0.83%
12
CRNXCRINETICS PHARMACEUTICALS IN
92,700$4.3M0.58%
13
KRYSKRYSTAL BIOTECH INC
17,300$4.3M0.57%
14
AURAAura Biosciences, Inc.
360,483$2.0M0.26%
15
ZNTLZentalis Pharmaceuticals Inc.
1,323,327$1.8M0.24%
16
PYXSPyxis Oncology, Inc (formerly Apexigen)
326,810$375K0.05%
17
FDMT4D MOLECULAR THERAPEUTICS IN
44,311$332K0.04%
18
NUVB/WSNuvation Bio Inc.
646,057$213K0.03%
19
RZLTREZOLUTE INC
59,900$141K0.02%